Patritumab Deruxtecan Biologics License Application For Patients With Previously Treated Locally Advanced Or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

RefinitivLesedauer weniger als 1 min

PATRITUMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Loggen Sie sich ein oder erstellen Sie ein fortwährend kostenloses Konto, um diese News lesen zu können